Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic collaborations, and regulatory milestones.
Access curated press releases and news articles covering Curis’s pipeline developments, including its lead candidate emavusertib, partnership updates with Aurigene and Genentech, and financial performance. The resource is designed to help users track progress across hematologic and solid tumor indications while staying informed about licensing agreements and scientific advancements.
Content spans clinical trial results, FDA designations, earnings reports, and research publications. Bookmark this page for direct access to verified updates on Curis’s innovative approaches to modulating cancer pathways and expanding treatment options.
Curis Inc. (NASDAQ: CRIS) reported Q2 2024 financial results and operational updates. Key highlights include:
1. European Commission granted Orphan Drug Designation to emavusertib for PCNSL treatment.
2. Initial data for 15-20 R/R PCNSL patients expected by late 2024.
3. Positive preliminary data in R/R AML patients with FLT3 and SF mutations.
4. Q2 2024 net loss of $11.8 million ($2.03 per share) vs $12.0 million ($2.47 per share) in Q2 2023.
5. Revenues increased to $2.5 million in Q2 2024 from $2.2 million in Q2 2023.
6. Cash position of $28.4 million as of June 30, 2024, expected to fund operations into Q1 2025.
Curis Inc. (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced its plans to release second quarter 2024 financial and operating results on August 1, 2024, at 8:00 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800)-836-8184 from the US or (646)-357-8785 from other locations. A live audio webcast will be available on the investor section of the Curis website, with a replay accessible later at www.curis.com.
Curis, a biotechnology company listed on NASDAQ under the ticker CRIS, announced that its President and CEO, James Dentzer, will present at the Jones Healthcare Seaside Summit 2024. The presentation is scheduled for July 15, 2024, at 8:00 a.m. PT (11:00 a.m. ET). Curis focuses on developing emavusertib (CA-4948), an orally available small molecule IRAK4 inhibitor. A live webcast and an archived replay of the presentation will be accessible through the Events & Presentations section of Curis's website.
Curis announced that its independent Compensation Committee approved an inducement stock option grant for a new employee. The grant, effective July 1, 2024, allows the employee to purchase 25,000 shares of Curis common stock at the closing price on the grant date. The stock options have a 10-year term and vest over four years, with 25% vesting after the first year and 6.25% vesting every three months thereafter. This grant is outside of the company's existing stock incentive plan and aims to encourage the new employee to join Curis.
Curis announced updated data from its ongoing TakeAim Leukemia study, focusing on emavusertib (CA-4948) treatment for relapsed/refractory AML patients with FLT3 and U2AF1/SF3B1 mutations. The dataset increased from 5 to 30 patients, showing 6 objective responses in 11 FLT3m patients and 4 in 18 SFm patients. Notable responses included complete remission and morphologic leukemia-free state. The data also highlighted increased neutrophil counts in several ongoing patients, indicating potential clinical benefits. These findings will be presented at the ASCO and EHA conferences.
Curis, Inc. (NASDAQ: CRIS) will present updated data from the TakeAim Leukemia study on May 14, 2024. The company focuses on emavusertib (CA-4948), an IRAK4 inhibitor. A conference call will follow the presentation.
Curis, Inc. (NASDAQ: CRIS) provided a business update and financial results for Q1 2024. The company will present clinical data on emavusertib for leukemia patients, updated data for R/R AML, and upcoming milestones for ongoing studies. Financially, Curis reported a net loss of $11.9 million, a decrease in revenue, and increased R&D and G&A expenses. Cash, cash equivalents, and investments totaled $40.7 million as of March 31, 2024.
Curis, Inc. (NASDAQ: CRIS) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The company is focused on developing emavusertib (CA-4948), an IRAK4 inhibitor. Investors can access the call via phone or the company's website.
